Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Childhood AML

PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group

Leukemia volume 18, pages 1831–1834 (2004)Cite this article

Abstract

The PTPN11 gene encodes SHP-2, a nonreceptor protein tyrosine phosphatase that relays signals from activated growth factor receptors to p21ras (Ras) and other signaling molecules. Somatic PTPN11 mutations are common in patients with juvenile myelomonocytic leukemia (JMML) and have been reported in some other hematologic malignancies. We analyzed specimens from 278 pediatric patients with acute myelogenous leukemia (AML) who were enrolled on Children's Cancer Group trials 2941 and 2961 for PTPN11 mutations. Missense mutations of PTPN11 were detected in 11 (4%) of these samples. None of these patients had mutations in NRAS; however, one patient had evidence of a FLT3 alteration. Four of the patients with PTPN11 mutations (36%) were boys with French–American–British (FAB) morphology M5 AML (P=0.012). Patients with mutations also presented with elevated white blood cell counts. There was no difference in clinical outcome for patients with and without PTPN11 mutations. These characteristics identify a subset of pediatric AML with PTPN11 mutations that share clinical and biologic features with JMML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.

    Article  CAS  PubMed  Google Scholar 

  2. Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003; 102: 1474–1479.

    Article  CAS  PubMed  Google Scholar 

  3. Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990; 76: 801–807.

    CAS  PubMed  Google Scholar 

  4. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.

    CAS  PubMed  Google Scholar 

  5. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE . Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92: 441–450.

    Article  CAS  PubMed  Google Scholar 

  6. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465–468.

    Article  CAS  PubMed  Google Scholar 

  7. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002; 70: 1555–1563.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Arico M, Biondi A, Pui CH . Juvenile myelomonocytic leukemia. Blood 1997; 90: 479–488.

    CAS  PubMed  Google Scholar 

  9. Emanuel PD, Shannon KM, Castleberry RP . Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today 1996; 2: 468–475.

    Article  CAS  PubMed  Google Scholar 

  10. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89: 3534–3543.

    CAS  PubMed  Google Scholar 

  11. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.

    Article  CAS  PubMed  Google Scholar 

  12. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103: 2325–2331.

    Article  CAS  PubMed  Google Scholar 

  13. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Liu-Mares W et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 914–919.

    Article  CAS  PubMed  Google Scholar 

  14. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Tjoa T et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000; 6 (Suppl 1): S39–S44.

    PubMed  Google Scholar 

  15. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89–94.

    Article  CAS  PubMed  Google Scholar 

  16. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  17. Greenwood M . Reports on Public Health and Medical Subjects, Vol. 33. London: His Majesty's Stationery Office, 1926.

    Google Scholar 

  18. Peto R, Peto J . Asymptotically efficient rank in variant test procedures. J R Stat Soc A 1972; 135: 185–206.

    Article  Google Scholar 

  19. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  20. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA. 2004; 101: 597–602.

    Article  CAS  PubMed  Google Scholar 

  21. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113: 528–538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jung A, Bechthold S, Pfluger T, Renner C, Ehrt O . Orbital rhabdomyosarcoma in Noonan syndrome. J Pediatr Hematol Oncol 2003; 25: 330–332.

    Article  PubMed  Google Scholar 

  23. Agras PI, Baskin E, Sakallioglu AE, Arda IS, Ayter S, Oguzkan S et al. Neurofibromatosis – Noonan's syndrome with associated rhabdomyosarcoma of the urinary bladder in an infant: case report. J Child Neurol 2003; 18: 68–72.

    Article  PubMed  Google Scholar 

  24. Bisogno G, Murgia A, Mammi I, Strafella MS, Carli M . Rhabdomyosarcoma in a patient with cardio-facio-cutaneous syndrome. J Pediatr Hematol Oncol 1999; 21: 424–427.

    Article  CAS  PubMed  Google Scholar 

  25. Khan S, McDowell H, Upadhyaya M, Fryer A . Vaginal rhabdomyosarcoma in a patient with Noonan syndrome. J Med Genet 1995; 32: 743–745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Johannes JM, Garcia ER, De Vaan GA, Weening RS . Noonan's syndrome in association with acute leukemia. Pediatr Hematol Oncol 1995; 12: 571–575.

    Article  CAS  PubMed  Google Scholar 

  27. Klopfenstein KJ, Sommer A, Ruymann FB . Neurofibromatosis – Noonan syndrome and acute lymphoblastic leukemia: a report of two cases. J Pediatr Hematol Oncol 1999; 21: 158–160.

    Article  CAS  PubMed  Google Scholar 

  28. Bader-Meunier B, Tchernia G, Miélot F, Fontaine JL, Thomas C, Lyonnet S et al. Occurrence of myeloproliferative disorder in patients with the Noonan syndrome. J Pediatr 1997; 130: 885–889.

    Article  CAS  PubMed  Google Scholar 

  29. Bertola DR, Carneiro JD, D'Amico EA, Kim CA, Albano LM, Sugayama SM et al. Hematological findings in Noonan syndrome. Rev Hosp Clin Fac Med Sao Paulo 2003; 58: 5–8.

    Article  PubMed  Google Scholar 

  30. Massarano AA, Wood A, Tait RC, Stevens R, Super M . Noonan syndrome: coagulation and clinical aspects. Acta Paediatr 1996; 85: 1181–1185.

    Article  CAS  PubMed  Google Scholar 

  31. Witt DR, McGillivray BC, Allanson JE, Hughes HE, Hathaway WE, Zipursky A et al. Bleeding diathesis in Noonan syndrome: a common association. Am J Med Genet 1988; 31: 305–317.

    Article  CAS  PubMed  Google Scholar 

  32. Fragale A, Tartaglia M, Wu J, Gelb BD . Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 2004; 23: 267–277.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

MLL is supported by NIH Grant K23 CA80915, the US Army Chronic Myelogenous Leukemia Program (Project CM020058), the Hope Street Kids Foundation, the UCSF REAC intramural grants program, the Jeffrey and Karen Peterson Family Foundation, and by the Frank A Campini Foundation. Coded specimens from patients with pediatric AML were supplied by the Children's Oncology Group.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of California, San Francisco, CA, USA

    M L Loh, M G Reynolds, S Vattikuti, J W Cheng & C M Lee

  2. Comprehensive Cancer Center, University of California, San Francisco, CA, USA

    M L Loh

  3. The Children's Oncology Group, Arcadia, CA, USA

    R B Gerbing & T A Alonzo

  4. Department of Biostatistics, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

    T A Alonzo

  5. Program in Human Genetics, University of California, San Francisco, CA, USA

    E Carlson

  6. Children's Hospital of Philadelphia, Philadelphia, PA, USA

    B J Lange

  7. Department of Pediatrics, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    S Meshinchi

Authors
  1. M L Loh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M G Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Vattikuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R B Gerbing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T A Alonzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J W Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C M Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B J Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Meshinchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M L Loh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loh, M., Reynolds, M., Vattikuti, S. et al. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia 18, 1831–1834 (2004). https://doi.org/10.1038/sj.leu.2403492

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403492

Keywords

This article is cited by

Search

Advanced search

Quick links